A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Epistemonikos ID: 37c69f250e80461a404885b1ea857b777d6673c7
First added on: May 14, 2024